Premenopozal Hormon Reseptörü Pozitif Meme Kanserinde Adjuvan Endokrin Tedavi
Synopsis
Adjuvant endocrine therapy for premenopausal patients with hormone receptor-positive early breast cancer should be individualized according to clinicopathological recurrence risk, ovarian function, age, treatment tolerability, and fertility considerations. Tamoxifen monotherapy may be sufficient for patients at lower risk, whereas increasing recurrence risk may warrant the addition of ovarian function suppression (OFS), with an aromatase inhibitor (AI) plus OFS representing a more intensive option for higher-risk disease. The SOFT, TEXT, and ASTRRA trials have established the clinical benefit of OFS-based strategies, particularly in young patients and those at higher risk of recurrence. In high-risk HR-positive/HER2-negative disease, the addition of adjuvant CDK4/6 inhibitors to endocrine therapy has further expanded treatment options. Optimal treatment duration, extended endocrine therapy, treatment adherence, bone health, and pregnancy planning are also important components of long-term management. This chapter reviews current evidence and risk-adapted approaches to adjuvant endocrine therapy in premenopausal patients with early breast cancer.
References
Pan H, Gray R, Braybrooke J, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-1846. doi:10.1056/NEJMoa1701830.
Francis PA, Pagani O, Fleming GF, et al. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer. Ann Oncol. 2026;37(10):1367-1385. doi:10.1016/j.annonc.2026.05.704.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23(3):382-392. doi:10.1016/S1470-2045(21)00758-0.
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689-1701. doi:10.1200/JCO.2015.65.9573.
Bernhard J, Luo W, Ribi K, et al. Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials. Lancet Oncol. 2015;16(7):848-858. doi:10.1016/S1470-2045(15)00049-2.
Baek SY, Noh WC, Ahn SH, et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J Clin Oncol. 2023;41(31):4864-4871. doi:10.1200/JCO.23.00557.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials. Lancet. 2026;407(10540):1699-1711. doi:10.1016/S0140-6736(26)00313-2.
Ayala de la Peña F, Antolín Novoa S, Gavilá Gregori J, et al. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025). Clin Transl Oncol. 2026;28(1):105-125. doi:10.1007/s12094-025-04139-x.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-784. doi:10.1016/S0140-6736(11)60993-8.
Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436-446. doi:10.1056/NEJMoa1412379.
Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221-2231. doi:10.1200/JCO.2015.64.3171.
Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122-137. doi:10.1056/NEJMoa1803164.
Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107-118. doi:10.1056/NEJMoa1404037.
Pagani O, Walley BA, Fleming GF, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol. 2023;41(7):1376-1382. doi:10.1200/JCO.22.01064.
Davies C, Pan H, Godwin J, et al; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816. doi:10.1016/S0140-6736(12)61963-1.
Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022;33(11):1097-1118. doi:10.1016/j.annonc.2022.07.007.
Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2026;24(7):e260033. doi:10.6004/jnccn.2026.0033.
Trenou KC, Mésidor M, Diorio C, Eslami A, Talbot D. Effects of extended aromatase inhibitors in women with hormone-dependent breast cancer who have already received five years of adjuvant hormone therapy: a systematic review and meta-analysis. Bull Cancer. 2024;111(4):356-362. doi:10.1016/j.bulcan.2023.12.016.
Valenza C, Zheng Y, Milano M, et al. Extended endocrine therapy following 5 years of adjuvant luteinizing hormone-releasing hormone agonist in premenopausal patients with node-positive, hormone receptor-positive breast cancer: a cohort study. J Clin Oncol. 2026;44(6):486-496. doi:10.1200/JCO-25-01660.
Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42(9):987-993. doi:10.1200/JCO.23.01994.
Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10(11):105858. doi:10.1016/j.esmoop.2025.105858.
Hadji P, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: an updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol. 2025;53:100694.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4.
Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313-320.
Partridge AH, Niman SM, Ruggeri M, et al; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656. doi:10.1056/NEJMoa2212856.
Pagani O, Niman SM, Ruggeri M, et al; International Breast Cancer Study Group and the POSITIVE Trial Consortium. Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial. Ann Oncol. 2026;37(9):1230-1241. doi:10.1016/j.annonc.2026.05.699.